Lymphoma

Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic malignancies.

Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma.

Despite being declared cancer-free after initial treatment, I grapple with survivor's guilt, questioning why my lymphoma responded to therapy while others did not.

Throughout the year, CURE® contributors shared personal stories and reflections highlighting the multifaceted nature of cancer care.

Monjuvi plus Revlimid and Rituxan demonstrated improved progression-free survival for patients with relapsed or refractory follicular lymphoma.

After sharing his cancer story online, Jace Yawnick is in a state of technical remission after receiving a diagnosis of non-Hodgkin lymphoma at age 25.

The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated, according to data from a retrospective analysis.

Watching "Scrooge" every Christmas made me reflect on my own journey, where my past struggles with illness taught me valuable lessons about forgiveness, love and joy.

This marks the first mesenchymal stromal cell therapy approved by the FDA for children with acute graft versus host disease.

When you’ve had cancer do doctors assume every ailment is cancer for you?

Patients with advanced Hodgkin lymphoma demonstrated significantly improved survival benefits with an Opdivo regimen versus an Adcetris regimen.

As a four-time cancer survivor, I can tell you that survivorship means many things to each survivor.

From producer Quincy Jones’ death from pancreatic cancer to an inspiring moment between The Rock and a fan at a store, here’s what’s happening in the cancer space this week.

Whenever I get sick, I experience a few side effects that usually go away, but unexplained weight loss becomes a problem for me.

CAR-T cell therapies administered in an outpatient setting may be safe and feasible without intensive remote monitoring in hematologic malignancies.

Recently, I met a fellow cancer survivor but after talking with her about cancer, I realized she had a different perspective than I did.

Adcetris plus Revlimid/Rituxan significantly improved outcomes versus Revlimid/Rituxan alone in relapsed/refractory lymphoma.

From Roger O’Donnell announcing his aggressive lymphoma diagnosis to “Love Is Blind’s” Shaina Hurley opening up about her cervical cancer while three months pregnant, here’s what’s happening in the oncology space this week.

Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma.

Living with chronic small lymphocytic lymphoma for the past 15 years has taught me some very valuable lessons, from dieting to managing anxiety.

Treatment with Yescarta for B-cell lymphoma may be promising within the first five years, but the risk of secondary cancers may reduce survival long term.

Fatigue is a common side effect that may linger for years following cancer treatment. Experts and survivors talk about ways to help find a balance between life and fatigue.

The FDA granted a fast track designation to BGB-16673, a novel drug used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma.

The militaristic terminology of “fighting a disease” does not sit well with me. After being diagnosed, I wasn’t fighting. I was reacting.

In August 2024, the FDA approved six new cancer treatments, including some that haven’t previously been approved.

Niktimvo was approved for adults and children with chronic, pretreated graft-versus-host disease.

One researcher explains the science behind Lymphir, recently approved by the FDA for relapsed/refractory cutaneous T-cell lymphoma.

From Patti Yasutake’s death from cancer to Olympic water polo player’s husband’s rare cancer diagnosis, here’s what’s happening in the oncology space this week.

When I started experiencing symptoms of an infection, I was worried that my follicular lymphoma had returned.

Lymphir, an immunotherapy, has been approved by the FDA to treat patients with relapsed or refractory cutaneous T-cell lymphoma.